These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28485846)

  • 1. Oxytocin and Migraine Headache.
    Tzabazis A; Kori S; Mechanic J; Miller J; Pascual C; Manering N; Carson D; Klukinov M; Spierings E; Jacobs D; Cuellar J; Frey WH; Hanson L; Angst M; Yeomans DC
    Headache; 2017 May; 57 Suppl 2():64-75. PubMed ID: 28485846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal civamide for the acute treatment of migraine headache.
    Diamond S; Freitag F; Phillips SB; Bernstein JE; Saper JR
    Cephalalgia; 2000 Jul; 20(6):597-602. PubMed ID: 11075845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxytocin receptor: Expression in the trigeminal nociceptive system and potential role in the treatment of headache disorders.
    Tzabazis A; Mechanic J; Miller J; Klukinov M; Pascual C; Manering N; Carson DS; Jacobs A; Qiao Y; Cuellar J; Frey WH; Jacobs D; Angst M; Yeomans DC
    Cephalalgia; 2016 Sep; 36(10):943-50. PubMed ID: 26590611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No side-effects of single intranasal oxytocin administration in middle childhood.
    Verhees MWFT; Houben J; Ceulemans E; Bakermans-Kranenburg MJ; van IJzendoorn MH; Bosmans G
    Psychopharmacology (Berl); 2018 Aug; 235(8):2471-2477. PubMed ID: 29915962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor.
    Jansen-Olesen I; Baun M; Amrutkar DV; Ramachandran R; Christophersen DV; Olesen J
    Neuropeptides; 2014 Apr; 48(2):53-64. PubMed ID: 24508136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of 5-HT7 receptor reduces CGRP release in an experimental model for migraine.
    Wang X; Fang Y; Liang J; Yin Z; Miao J; Luo N
    Headache; 2010 Apr; 50(4):579-87. PubMed ID: 20236348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR
    Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
    Bigal ME; Dodick DW; Rapoport AM; Silberstein SD; Ma Y; Yang R; Loupe PS; Burstein R; Newman LC; Lipton RB
    Lancet Neurol; 2015 Nov; 14(11):1081-90. PubMed ID: 26432182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topiramate in Migraine Prevention: A 2016 Perspective.
    Silberstein SD
    Headache; 2017 Jan; 57(1):165-178. PubMed ID: 27902848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal Oxytocin Attenuates Reactive and Ongoing, Chronic Pain in a Model of Mild Traumatic Brain Injury.
    Meidahl AC; Eisenried A; Klukinov M; Cao L; Tzabazis AZ; Yeomans DC
    Headache; 2018 Apr; 58(4):545-558. PubMed ID: 29266199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Episodic dural stimulation in awake rats: a model for recurrent headache.
    Oshinsky ML; Gomonchareonsiri S
    Headache; 2007; 47(7):1026-36. PubMed ID: 17635594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
    Tepper SJ; Cady RK; Silberstein S; Messina J; Mahmoud RA; Djupesland PG; Shin P; Siffert J
    Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing Episodic Migraine With Caloric Vestibular Stimulation: A Randomized Controlled Trial.
    Wilkinson D; Ade KK; Rogers LL; Attix DK; Kuchibhatla M; Slade MD; Smith LL; Poynter KP; Laskowitz DT; Freeman MC; Hoffer ME; Saper JR; Scott DL; Sakel M; Calhoun AH; Black RD
    Headache; 2017 Jul; 57(7):1065-1087. PubMed ID: 28656612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signaling Interaction between Facial and Meningeal Inputs of the Trigeminal System Mediates Peripheral Neurostimulation Analgesia in a Rat Model of Migraine.
    Wang S; Wang J; Liu K; Bai W; Cui X; Han S; Gao X; Zhu B
    Neuroscience; 2020 May; 433():184-199. PubMed ID: 32171818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of intranasal administration of oxytocin on fear recognition.
    Fischer-Shofty M; Shamay-Tsoory SG; Harari H; Levkovitz Y
    Neuropsychologia; 2010 Jan; 48(1):179-84. PubMed ID: 19747930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study.
    Winner P; Rothner AD; Wooten JD; Webster C; Ames M
    Headache; 2006 Feb; 46(2):212-22. PubMed ID: 16492230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype in young adults with high-functioning autism: a 24-week randomized clinical trial.
    Kosaka H; Okamoto Y; Munesue T; Yamasue H; Inohara K; Fujioka T; Anme T; Orisaka M; Ishitobi M; Jung M; Fujisawa TX; Tanaka S; Arai S; Asano M; Saito DN; Sadato N; Tomoda A; Omori M; Sato M; Okazawa H; Higashida H; Wada Y
    Transl Psychiatry; 2016 Aug; 6(8):e872. PubMed ID: 27552585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.